Bazı doğal bileşiklerin antioksidan, anti-elastaz, anti-kolajenaz, anti-hyaluronidaz ve meme kanseri karşıtı aktiviteleri

Öz

Doğal ürünler, çeşitli biyolojik aktiviteleri, geniş kaynak yelpazeleri ve yapısal çeşitlilikleri nedeniyle çağdaş ilaç geliştirme alanında büyük bir potansiyel sunmaktadır. Bu araştırmada, kolajenaz, elastaz ve hiyalüronidaz enzimleri, Clusiacyclol A, Cycloolivil ve Cyclopenol molekülleri tarafından, Clusiacyclol A için sırasıyla 11,35 ± 1,24, 75,36 ± 11,73 ve 25,17 ± 3,38 µM; Cycloolivil için sırasıyla 19,42 ± 2,66, 84,16 ± 6,80 ve 94,36 ± 8,46 µM; ve Cyclopenol için sırasıyla 0,65 ± 0,04, 50,24 ± 5,07 ve 66,01 ± 10,83 µM olmak üzere mükemmel ila iyi IC50 değerleriyle inhibe edilmiştir. Bu kimyasal bileşikler bu nedenle kanser hücrelerini ve enzimleri baskılayabilir. Dahası, bu maddeler düşük konsantrasyonlarda bile meme kanseri hücrelerinin canlılığını belirgin şekilde azalttı. Ek olarak, tüm bileşiklerin 100 M dozunda meme kanseri hücrelerinin canlılığı önemli ölçüde azaldı. Clusiacyclol A, Cycloolivil ve Cyclopenol'ün hiyalüronidaz, kollajenaz ve elastaz üzerindeki kimyasal aktiviteleri, moleküler kenetlenme analizi, MM/GBSA hesaplaması ve moleküler dinamik (MD) simülasyonu yapılarak değerlendirildi. Bu maddelerin kanser karşıtı özellikleri, Hs 281.T, MDA-MB-468, MCF7, CAMA-1, SK-BR-3 ve NMU dahil olmak üzere meme kanseri hücreleri üzerinde değerlendirildi. İn silico teknikler kullanılarak, androjen reseptörü, progesteron reseptörü, östrojen reseptörü ve CD47 dahil olmak üzere birkaç ifade edilen yüzey reseptör proteini incelendi.

Anahtar Kelimeler

• Doğal bileşikler
• antioksidan
• enzim inhibisyonu
• moleküler kenetlenme
• meme kanseri karşıtı

Anti-Oxidant, Anti-Elastase, Anti-Collagenase, Anti-Hyaluronidase, Anti-Breast Cancer Activities of Some Natural Compounds

Öz

Natural products provide great potential for contemporary medication development due to their diverse biological activity, large range of sources, and structural diversity. In this investigation, the enzymes collagenase, elastasei and hyaluronidase were inhibited by Clusiacyclol A, Cycloolivil, and Cyclopenol molecules with excellent to good IC50 values of 11.35 ± 1.24, 75.36 ± 11.73, and 25.17 ± 3.38 µM for Clusiacyclol A, and 19.42 ± 2.66, 84.16±6.80, and 94.36± 8.46 µM for Cycloolivil, and 0.65±0.04, 50.24±5.07, and 66.01± 10.83 µM for Cyclopenol, respectively. These chemical compounds therefore might be able to suppress cancer cells and enzymes. Moreover, these substances markedly decreased the viability of breast cancer cells, even at low concentrations. Additionally, the impacts of breast cancer cells was significantly reduced at a 100 µM dosage of all compounds. The chemical bioactivities of Clusiacyclol A, Cycloolivil, and Cyclopenol against collagenase, hyaluronidase, and elastase were assessed by performing the molecular docking analysis, molecular dynamics (MD) simulation and MM/GBSA calculation. These substances' anti-cancer properties were evaluated about breast cancer cells, including Hs 281.T, SK-BR-3, MCF7, CAMA-1, MDA-MB-468, and NMU. Using in-silico techniques, they examined a few expressed surface receptor proteins, including the androgen receptor, progesterone receptor, estrogen receptor, and CD47.

Anahtar Kelimeler

• Natural compounds
• antioxidant
• enzyme inhibition
• molecular docking
• anti-breast cancer

Kaynakça

1. AbdulJabar, L. A., Al-Shawi, A. A., & Mutlaq, D. Z. (2021). Anti-liver and anti-breast cancer activities of 2-thioxo-4-imidazolidinone derivatives. Medicinal Chemistry Research, 30(10), 1943-1953.
2. Alibolandi, M., Abnous, K., Sadeghi, F., Hosseinkhani, H., Ramezani, M., & Hadizadeh, F. (2016). Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: in vitro and in vivo evaluation. International Journal of Pharmaceutics, 500(1-2), 162-178.
3. Asadikaram, G., Poustforoosh, A., Pardakhty, A., Torkzadeh-Mahani, M., & Nematollahi, M. H. (2021). Niosomal virosome derived by vesicular stomatitis virus glycoprotein as a new gene carrier. Biochemical and Biophysical Research Communications, 534, 980-987.
4. Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., & Supuran, C. T. (2021). Natural products in drug discovery: advances and opportunities. Nature reviews Drug discovery, 20(3), 200-216.
5. Aware, C. B., Patil, D. N., Suryawanshi, S. S., Mali, P. R., Rane, M. R., Gurav, R. G., & Jadhav, J. P. (2022). Natural bioactive products as promising therapeutics: A review of natural product-based drug development. South African Journal of Botany, 151, 512-528.
6. Bajalovic, N., Or, Y. Z., Woo, A. R., Lee, S. H., & Lin, V. C. (2022). High levels of progesterone receptor B in MCF-7 cells enable radical anti-tumoral and anti-estrogenic effect of progestin. Biomedicines, 10(8), 1860.
7. Barbosa, A. M., & Martel, F. (2020). Targeting glucose transporters for breast cancer therapy: the effect of natural and synthetic compounds. Cancers, 12(1), 154.
8. Chen, X., Liang, L., & Han, C. (2020). Borate suppresses the scavenging activity of gallic acid and plant polyphenol extracts on DPPH radical: A potential interference to DPPH assay. Lwt, 131, 109769.

9. Chopra, B., & Dhingra, A. K. (2021). Natural products: A lead for drug discovery and development. Phytotherapy Research, 35(9), 4660-4702.
10. Deniz, F. S. S., Orhan, I. E., & Duman, H. (2021). Profiling cosmeceutical effects of various herbal extracts through elastase, collagenase, tyrosinase inhibitory and antioxidant assays. Phytochemistry Letters, 45, 171-183.
11. Diniz do Nascimento, L., Barbosa de Moraes, A. A., Santana da Costa, K., Pereira Galúcio, J. M., Taube, P. S., Leal Costa, C. M., ... & Guerreiro de Faria, L. J. (2020). Bioactive natural compounds and antioxidant activity of essential oils from spice plants: New findings and potential applications. Biomolecules, 10(7), 988.
12. Fazel, R., Hassani, B., Zare, F., Jokar Darzi, H., Khoshneviszadeh, M., Poustforoosh, A., ... & Sadeghpour, H. (2024). Design, synthesis, in silico ADME, DFT, molecular dynamics simulation, anti-tyrosinase, and antioxidant activity of some of the 3-hydroxypyridin-4-one hybrids in combination with acylhydrazone derivatives. Journal of Biomolecular Structure and Dynamics, 42(18), 9518-9528.
13. Gaber, N. B., El-Dahy, S. I., & Shalaby, E. A. (2023). Comparison of ABTS, DPPH, permanganate, and methylene blue assays for determining antioxidant potential of successive extracts from pomegranate and guava residues. Biomass Conversion and Biorefinery, 13(5), 4011-4020.
14. Go, Y. J., Kim, Y. E., Kim, H. N., Lee, E. H., Cho, E. B., Alex, A., & Cho, Y. J. (2019). Inhibition Effect Against Elastase, Collagenase, Hyaluronidase and Anti-oxidant Activity of Thinning Green Ball Apple. In Proceedings of the Plant Resources Society of Korea Conference (pp. 63-63). The Plant Resources Society of Korea.
15. He, H., Li, H., Akanji, T., Niu, S., Luo, Z., Li, D., ... & Ma, H. (2021). Synthesis and biological evaluations of oleanolic acid indole derivatives as hyaluronidase inhibitors with enhanced skin permeability. Journal of Enzyme Inhibition and Medicinal Chemistry, 36(1), 1664-1677.
16. Hering, A., Stefanowicz-Hajduk, J., Gucwa, M., Wielgomas, B., & Ochocka, J. R. (2023). Photoprotection and antiaging activity of extracts from honeybush (Cyclopia sp.)—In vitro wound healing and inhibition of the skin extracellular matrix enzymes: Tyrosinase, collagenase, elastase and hyaluronidase. Pharmaceutics, 15(5), 1542.
17. Hyatt, D. C., & Ceresa, B. P. (2008). Cellular localization of the activated EGFR determines its effect on cell growth in MDA-MB-468 cells. Experimental cell research, 314(18), 3415-3425.
18. Islam, M. R., Islam, F., Nafady, M. H., Akter, M., Mitra, S., Das, R., ... & Cavalu, S. (2022). Natural small molecules in breast cancer treatment: understandings from a therapeutic viewpoint. Molecules, 27(7), 2165.
19. Jahantigh, H., Ahmadi, N., Lovreglio, P., Stufano, A., Enayatkhani, M., Shahbazi, B., & Ahmadi, K. (2023). Repurposing antiviral drugs against HTLV-1 protease by molecular docking and molecular dynamics simulation. Journal of Biomolecular Structure and Dynamics, 41(11), 5057-5066.
20. Jiratchayamaethasakul, C., Ding, Y., Hwang, O., Im, S. T., Jang, Y., Myung, S. W., ... & Lee, S. H. (2020). In vitro screening of elastase, collagenase, hyaluronidase, and tyrosinase inhibitory and antioxidant activities of 22 halophyte plant extracts for novel cosmeceuticals. Fisheries and Aquatic Sciences, 23(1), 6.
21. Joly, E., Vignon, F., & Rochefort, H. (1981). Growth regulation of two rat adenocarcinoma cell lines by dexamethasone and progesterone. Breast Cancer Research and Treatment, 1(4), 381-389.
22. Juliana, C., Lister, I. N. E., Girsang, E., Nasution, A. N., & Widowati, W. (2020). Antioxidant and elastase inhibitor from Black Soybean (Glycine max L.) and its compound (Daidzein). Journal of Biomedicine and Translational Research, 6(1), 11-14.
23. Kafa, A. H. T., Tüzün, G., Güney, E., Aslan, R., Sayın, K., Tüzün, B., & Ataseven, H. (2022). Synthesis, computational analyses, antibacterial and antibiofilm properties of nicotinamide derivatives. Structural Chemistry, 33(4), 1189-1197.
24. Lee, E. H., & Cho, Y. J. (2020). Elevation of anti-oxidative activity and inhibitory activities against tyrosinase, elastase, collagenase and hyaluronidase of Oplismenus undulatifolius by elicitor treatment. Journal of Applied Biological Chemistry, 63(3), 221-227.
25. Li, C., Wu, W., Tilley, M., Chen, R., Sun, X. S., Wang, W., & Li, Y. (2024). In vitro antioxidant properties of wheat bran extracts and their inhibitory effects on collagenase, elastase, and hyaluronidase. ACS Food Science & Technology, 4(8), 1960-1966.
26. Mehrabani, M., Raeiszadeh, M., Najafipour, H., Esmaeli Tarzi, M., Amirkhosravi, A., Poustforoosh, A., ... & Mehrabani, M. (2020). Evaluation of the cytotoxicity, antibacterial, antioxidant, and anti-inflammatory effects of different extracts of Punica granatum var. pleniflora. Journal of Kerman University of Medical Sciences, 27(5), 414-425.
27. Menck, K., Bleckmann, A., Wachter, A., Hennies, B., Ries, L., Schulz, M., ... & Binder, C. (2017). Characterisation of tumour-derived microvesicles in cancer patients’ blood and correlation with clinical outcome. Journal of Extracellular Vesicles, 6(1), 1340745.
28. Mihăşan, M. (2012). What in silico molecular docking can do for the ‘bench-working biologists’. Journal of biosciences, 37(Suppl 1), 1089-1095.
29. Naghiyev, F., Mamedov, I., Askerov, R., Taslimi, P., & Poustforoosh, A. (2022). Synthesis and biological activity of functionally substituted pyrimidine and pyran derivatives on the basis of isatylidene malononitriles. ChemistrySelect, 7(33), e202202006.
30. Porras, G., Chassagne, F., Lyles, J. T., Marquez, L., Dettweiler, M., Salam, A. M., ... & Quave, C. L. (2020). Ethnobotany and the role of plant natural products in antibiotic drug discovery. Chemical reviews, 121(6), 3495-3560.
31. Poustforoosh, A. (2024). Investigation on the structural and dynamical properties of cationic, anionic, and catanionic niosomes as multifunctional controlled drug delivery system for cabozantinib. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 687, 133547.
32. Poustforoosh, A. (2024). The impact of cationic/anionic ratio on the physicochemical aspects of catanionic niosomes as a promising carrier for anticancer drugs. Journal of Molecular Liquids, 408, 125338.
33. Poustforoosh, A., Faramarz, S., Nematollahi, M. H., Hashemipour, H., Negahdaripour, M., & Pardakhty, A. (2022). In silico SELEX screening and statistical analysis of newly designed 5mer peptide-aptamers as Bcl-xl inhibitors using the Taguchi method. Computers in Biology and Medicine, 146, 105632.
34. Poustforoosh, A., Hashemipour, H., Pardakhty, A., & Pour, M. K. (2022). Preparation of nano‐micelles of meloxicam for transdermal drug delivery and simulation of drug release: A computational supported experimental study. The Canadian Journal of Chemical Engineering, 100(11), 3428-3436.
35. Poustforoosh, A., Nematollahi, M. H., Hashemipour, H., & Pardakhty, A. (2022). Recent advances in Bio-conjugated nanocarriers for crossing the Blood-Brain Barrier in (pre-) clinical studies with an emphasis on vesicles. Journal of Controlled Release, 343, 777-797.
36. Poustforoosh, A., Faramarz, S., Nematollahi, M. H., Hashemipour, H., Tüzün, B., Pardakhty, A., & Mehrabani, M. (2022). 3D‐QSAR, molecular docking, molecular dynamics, and ADME/T analysis of marketed and newly designed flavonoids as inhibitors of Bcl‐2 family proteins for targeting U‐87 glioblastoma. Journal of Cellular Biochemistry, 123(2), 390-405.
37. Poustforoosh, A., Farmarz, S., Nematollahi, M. H., Hashemipour, H., & Pardakhty, A. (2022). Construction of Bio-conjugated nano-vesicles using non-ionic surfactants for targeted drug delivery: A computational supported experimental study. Journal of Molecular Liquids, 367, 120588.
38. Poustforoosh, A., Hashemipour, H., Tüzün, B., Azadpour, M., Faramarz, S., Pardakhty, A., ... & Nematollahi, M. H. (2022). The impact of D614G mutation of SARS-COV-2 on the efficacy of anti-viral drugs: A comparative molecular docking and molecular dynamics study. Current microbiology, 79(8), 241.
39. Poustforoosh, A., Faramarz, S., Negahdaripour, M., & Hashemipour, H. (2023). Modeling and affinity maturation of an anti-CD20 nanobody: a comprehensive in-silico investigation. Scientific Reports, 13(1), 582.
40. Poustforoosh, A., Faramarz, S., Negahdaripour, M., Tüzün, B., & Hashemipour, H. (2024). Tracing the pathways and mechanisms involved in the anti-breast cancer activity of glycyrrhizin using bioinformatics tools and computational methods. Journal of Biomolecular Structure and Dynamics, 42(2), 819-833.
41. Poustforoosh, A., Faramarz, S., Negahdaripour, M., Tüzün, B., & Hashemipour, H. (2024). Investigation on the mechanisms by which the herbal remedies induce anti-prostate cancer activity: uncovering the most practical natural compound. Journal of Biomolecular Structure and Dynamics, 42(7), 3349-3362.
42. Poustforoosh, A., Faramarz, S., Negahdaripour, M., Tüzün, B., & Hashemipour, H. (2024). Tracing the pathways and mechanisms involved in the anti-breast cancer activity of glycyrrhizin using bioinformatics tools and computational methods. Journal of Biomolecular Structure and Dynamics, 42(2), 819-833.
43. Poustforoosh, A., Hashemipour, H., Tüzün, B., Pardakhty, A., Mehrabani, M., & Nematollahi, M. H. (2021). Evaluation of potential anti-RNA-dependent RNA polymerase (RdRP) drugs against the newly emerged model of COVID-19 RdRP using computational methods. Biophysical chemistry, 272, 106564.
44. Poustforoosh, A., Faramarz, S., Nematollahi, M. H., Mahmoodi, M., & Azadpour, M. (2024). Correction: structure-based drug design for targeting IRE1: an in silico approach for treatment of cancer. Drug Research, 74(02), e1-e1.
45. Rashedinia, M., Rasti Arbabi, Z., Sabet, R., Emami, L., Poustforoosh, A., & Sabahi, Z. (2023). Comparison of protective effects of phenolic acids on protein glycation of BSA supported by in vitro and docking studies. Biochemistry Research International, 2023(1), 9984618.
46. Rastelli, G., Pellati, F., Pinzi, L., & Gamberini, M. C. (2020). Repositioning natural products in drug discovery. Molecules, 25(5), 1154.
47. Sadeghian, S., Zare, F., Khoshneviszadeh, M., Hafshejani, A. F., Salahshour, F., Khodabakhshloo, A., ... & Sadeghpour, H. (2024). Synthesis, biological evaluation, molecular docking, MD simulation and DFT analysis of new 3-hydroxypyridine-4-one derivatives as anti-tyrosinase and antioxidant agents. Heliyon, 10(15).
48. Schrödinger Release 2021-3. (2021a). Maestro, S., LLC, New York, NY.
49. Schrödinger Release 2021-3. (2021b). Protein Preparation Wizard; Epik, S., LLC, New York, NY, 2016; Impact, Schrödinger, LLC, New York, NY, 2016; Prime, Schrödinger , LLC, New York, NY.
50. Schrödinger Release 2021-3. (2021c). LigPrep, S., LLC, New York, NY.
51. Schrödinger Release 2021-3: Desmond Molecular Dynamics System, D.E.S.R., New York, NY, 2021. Maestro-Desmond Interoperability Tools, Schrödinger, New York, NY, 2021.
52. Scott, J. S., Moss, T. A., Balazs, A., Barlaam, B., Breed, J., Carbajo, R. J., ... & Yang, W. (2020). Discovery of AZD9833, a potent and orally bioavailable selective estrogen receptor degrader and antagonist. Journal of medicinal chemistry, 63(23), 14530-14559.
53. Sibuh, B. Z., Khanna, S., Taneja, P., Sarkar, P., & Taneja, N. K. (2021). Molecular docking, synthesis and anticancer activity of thiosemicarbazone derivatives against MCF-7 human breast cancer cell line. Life Sciences, 273, 119305.
54. Takatsuka, M., Goto, S., Kobayashi, K., Otsuka, Y., & Shimada, Y. (2022). Evaluation of pure antioxidative capacity of antioxidants: ESR spectroscopy of stable radicals by DPPH and ABTS assays with singular value decomposition. Food Bioscience, 48, 101714.
55. Taysi, M. R., Kirici, M., Kirici, M., Tuzun, B., & Poustforoosh, A. (2024). Antioxidant enzyme activities, molecular docking studies, MM-GBSA, and molecular dynamic of chlorpyrifos in freshwater fish Capoeta umbla. Journal of biomolecular structure and dynamics, 42(1), 163-176.
56. Türkan, F., Taslimi, P., Cabir, B., Ağırtaş, M. S., Erden, Y., Celebioglu, H. U., ... & Gulcin, I. (2022). Co and Zn Metal phthalocyanines with bulky substituents: anticancer, antibacterial activities and their inhibitory effects on some metabolic enzymes with molecular docking studies. Polycyclic Aromatic Compounds, 42(7), 4475-4486.
57. Wang, Y., Yu, Y., & Zhang, Y. (2024). Therapeutic properties and enzyme inhibition potentials of some natural compounds on hyaluronidase, collagenase, and elastase with molecular docking studies. Macromolecular Research, 32(5), 475-491.
58. Yumei, Z., Xiaoying, Z., Xiaoya, Z., Yihan, W., Jiayi, S., Lüyin, Z., & Wei, G. (2023). Design, synthesis and in vitro anti-cancer activity of novel ethyl 4-oxo-2-iminothiazolidin-5-ylidene acetates. Chinese Journal of Organic Chemistry, 43(4), 1452.